Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo

被引：0
|
作者：
Van Cutsem, E.
Seitz, J. F.
Raoul, J.
Valle, J. W.
Faivre, S. J.
Patyna, S.
Klademenos, D.
Lu, D.
Chao, R. C.
Raymond, E.
机构：
[1] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium
[2] La Timone Univ Hosp, Marseille, France
[3] Ctr Eugene Marquis, Rennes, France
[4] European Univ Brittany, Rennes, France
[5] Christie NHS Fdn Trust, Dept Med Oncol, Manchester, Lancs, England
[6] Hop Beaujon, Clichy, France
[7] Pfizer, La Jolla, CA USA
[8] Pfizer Oncol, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 04期
关键词：
D O I：
10.1200/jco.2011.29.4_suppl.249
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
249
引用
收藏
页数：1
相关论文
共 50 条
  • [11] Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
    Carmona-Bayonas, Alberto
    Jimenez-Fonseca, Paula
    Lamarca, Angela
    Barriuso, Jorge
    Castano, Angel
    Benavent, Marta
    Alonso, Vicente
    Riesco-Martinez, Maria del Carmen
    Alonso-Gordoa, Teresa
    Custodio, Ana
    Sanchez Canovas, Manuel
    Hernando Cubero, Jorge
    Lopez, Carlos
    Lacasta, Adelaida
    Fernandez Montes, Ana
    Marazuela, Monica
    Crespo, Guillermo
    Escudero, Pilar
    Diaz, Jose Angel
    Feliciangeli, Eduardo
    Gallego, Javier
    Llanos, Marta
    Segura, Angel
    Vilardell, Felip
    Percovich, Juan Carlos
    Grande, Enrique
    Capdevila, Jaume
    Valle, Juan W.
    Garcia-Carbonero, Rocio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (28) : 2571 - +
  • [12] The efficacy and safety of sunitinib in patients with advanced well-differentiated pancreatic neuroendocrine tumors.
    Raymond, Eric
    Kulke, Matthew H.
    Qin, Shukui
    Schenker, Michael
    Cubillo, Antonio
    Lou, Wenhui
    Tomasek, Jiri
    Thiis-Evensen, Espen
    Xu, Jianming
    Racz, Karoly
    Croitoru, Adina E.
    Khasraw, Mustafa
    Sedlackova, Eva
    Borbath, Ivan
    Ruff, Paul
    Oberstein, Paul Eliezer
    Ito, Tetsuhide
    Fernandez, Kathrine C.
    Rosbrook, Brad
    Fazio, Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [13] RESPONSE EVALUATION USING RECIST AND CHOI CRITERIA IN PATIENTS WITH WELL-DIFFERENTIATED PANCREATIC NEUROENDOCRINE TUMORS (PNET) TREATED WITH SUNITINIB OR EVEROLIMUS
    Dreyer, C.
    Hentic, O.
    Zappa, M.
    Hammel, P.
    Bouattour, M.
    Mateescu, C.
    Faivre, S.
    Ruszniewski, P.
    Raymond, E.
    ANNALS OF ONCOLOGY, 2012, 23 : 379 - 379
  • [14] Response evaluation using RECIST and CHOI criteria in patients with well-differentiated pancreatic neuroendocrine tumors (pNET) treated with sunitinib or everolimus
    Hentic, Olivia
    Dreyer, Chantal
    Zappa, Magaly
    Hammel, Pascal
    Mateescu, Cristian
    Bouattour, Mohamed
    Faivre, Sandrine J.
    Ruszniewski, Philippe
    Raymond, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [15] METFORMIN IMPACT ON PROGRESSION-FREE SURVIVAL IN ADVANCED PANCREATIC WELL-DIFFERENTIATED NEUROENDOCRINE TUMORS (PWDNETS). RETROSPECTIVE EVALUATION IN DIABETIC PATIENTS RECEIVING EVEROLIMUS PLUS OCTREOTIDE LAR TREATMENT
    Pusceddu, S.
    De Braud, F. G. M.
    Concas, L.
    Bregant, C.
    Festinese, F.
    Giacomelli, L.
    D'Autilia, E.
    Formisano, B.
    Mazzaferro, V.
    Buzzoni, R.
    ANNALS OF ONCOLOGY, 2014, 25
  • [16] Visceral Obesity Is Associated with Shorter Progression-Free Survival in Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Neoplasia
    Santos, Ana P.
    Rodrigues, Jessica
    Henrique, Rui
    Helena Cardoso, M.
    Monteiro, Mariana P.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [17] FDA Approval Summary: Sunitinib for the Treatment of Progressive Well-Differentiated Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors
    Blumenthal, Gideon M.
    Cortazar, Patricia
    Zhang, Jenny J.
    Tang, Shenghui
    Sridhara, Rajeshwari
    Murgo, Anthony
    Justice, Robert
    Pazdur, Richard
    ONCOLOGIST, 2012, 17 (08): : 1108 - 1113
  • [18] Angiogenic profiling in patients with advanced well-differentiated pancreatic neuroendocrine tumors treated with everolimus
    Cella, C. A.
    Spada, F.
    Galdy, S.
    Frezza, A. M.
    Catapano, M.
    Funicelli, L.
    Calleri, A.
    Zorzino, L.
    Mancuso, P.
    Radice, D.
    Fazio, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S449 - S449
  • [19] Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
    Lamarca, Angela
    Barriuso, Jorge
    Kulke, Matthew
    Borbath, Ivan
    Lenz, Heinz-Josef
    Raoul, Jean Luc
    Meropol, Neal J.
    Lombard-Bohas, Catherine
    Posey, James
    Faivre, Sandrine
    Raymond, Eric
    Valle, Juan W.
    BRITISH JOURNAL OF CANCER, 2018, 118 (02) : 181 - 188
  • [20] Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response
    Angela Lamarca
    Jorge Barriuso
    Matthew Kulke
    Ivan Borbath
    Heinz-Josef Lenz
    Jean Luc Raoul
    Neal J Meropol
    Catherine Lombard-Bohas
    James Posey
    Sandrine Faivre
    Eric Raymond
    Juan W Valle
    British Journal of Cancer, 2018, 118 : 181 - 188
12345